MedTrace Logo

Characterisation of the Immune Response to SARS-CoV-2 / COVID-19

NCT04729452 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 160

Last updated 2024-05-17

No results posted yet for this study

Summary

Emerging clinical details of the current SARS-CoV-2 pandemic have illustrated that there are multiple clinical presentations and outcomes of this viral infection. People with an infection have been reported to have a spectrum of disease from severe acute respiratory distress requiring ventilation, to mild respiratory or gastrointestinal symptoms and asymptomatic presentations. Mechanisms explaining the heterogeneity of host response to infection are yet to be characterised.

The aim of this project is to understand the host immune response to infection with SARS-CoV-2 over time in convalescent adults, including acquired immune responses, circulating levels of immune signalling molecules, gene expression profiling in peripheral blood and to identify host genetic variants associated with disease progressions or severity. Participants will be healthcare workers who had a diagnosis of COVID-19 (confirmed by positive RT-PCR assay) more than 28 days ago and have recovered and are employed by Cwm Taf Morgannwg University health board. Samples will be processed and analysed to explore immunological, host genetic factors and virological factors that explain pathogenesis and predict outcomes of infection.

Conditions

  • Covid19

Interventions

OTHER

blood test

blood test to test immune response to SARS-CoV-2

Sponsors & Collaborators

  • Cardiff University

    collaborator OTHER

  • University of Oxford

    collaborator OTHER

  • Cwm Taf University Health Board (NHS)

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2023-10-01
Completion
2023-12-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04729452 on ClinicalTrials.gov